Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD) (NOVA-1)

Key Inclusion Criteria [Stage 1 and Stage 2]: Presence of an active choroidal neovascularization (CNV) lesion secondary to age-related macular degeneration (AMD); Best corrected visual acuity (BCVA) between 80 and 35 letters (20/25 to 20/200 Snellen equivalent) in the study eye; BCVA greater than 34 letters (approximately 20/200 Snellen equivalent) in the non-study eye; Media clarity and pupillary dilation in the study eye sufficient for all planned study procedures; Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol; Other protocol-specified inclusion criteria may apply. [Stage 1]: Greater than or equal to 3 and less than or equal to 6 prior treatments of an ocular anti-VEGF medication within the 8 months prior to Screening in the study eye, with demonstrated anatomic response, as assessed by the Investigator. [Stage 2]: Treatment-naïve, or initial diagnosis of exudative neovascular age-related macular degeneration (nAMD) in the study eye within 9 months before Screening. Key Exclusion Criteria [Stage 1 and Stage 2]: History or current ocular disease in the study eye other than nAMD, that, might require medical or surgical intervention during the study; Structural damage to the macula that is likely to preclude improvement in visual acuity in the study eye after resolution of the nAMD; Any active intraocular or periocular infection or active intraocular inflammation; Treatment with ocular anti-VEGF product within 28-days before Week -1 [Stage 1] or Baseline [Stage 2]; Uncontrolled glaucoma in the study eye; Uncontrolled blood pressure; Females of child-bearing potential who are pregnant, intending to become pregnant, nursing, or who are not willing to use an acceptable form of contraception for the duration of the study; Other protocol-specified exclusion criteria may apply.